About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

D-Serine Monotherapy for Schizophrenia

NCT00215917·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Pesach Lichtenberg, M.D.
CONTACT
972-2-6221154 [email protected]

Lead

Herzog Hospital

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. DSM-IV criteria for chronic schizophrenia
2. Treatment resistant
3. aged 18-70
4. Two months on stable risperidone dose
5. PANSS positive symptom cluster score \>20
6. PANSS negative symptom cluster score \>22

You may not be if

1. Substance abuse
2. Concurrent DSM IV axis I disorder
3. Serious medical disorder
4. Concurrent drug therapy that can obscure the effect of risperidone or DSR.

The record

StatusUnknown

PhasePhase 1–2

Taking part40

Started—

UpdatedMay 3, 2006

Conditions

Where1

Herzog Hospital, Department of Psychiatry
Jerusalem, Israel

Clareo Health | D-Serine Monotherapy for Schizophrenia